Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis-Reference-Cited by-同舟云学术

Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis

Published:2018-04-27 Issue:8 Volume:24 Page:1695-1705
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Wang Yinghong¹,Abu-Sbeih Hamzah¹,Mao Emily²,Ali Noman²,Qiao Wei³,Trinh Van Anh⁴,Zobniw Chrystia⁴,Johnson Daniel Hartman⁵,Samdani Rashmi⁶,Lum Phillip¹,Shuttlesworth Gladis¹,Blechacz Boris¹,Bresalier Robert¹,Miller Ethan¹,Thirumurthi Selvi¹,Richards David¹,Raju Gottumukkala¹,Stroehlein John¹,Diab Adi⁷

Affiliation:

1. Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas

2. Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas

4. Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, Texas

5. Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

6. Department of Pathology/Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

7. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/8/1695/25153972/izy104.pdf

Reference19 articles.

1. Immune checkpoint blockade: a common denominator approach to cancer therapy;Topalian;Cancer Cell,2015

2. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

3. Cancer immunotherapy comes of age;Mellman;Nature,2011

4. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma;Postow;N Engl J Med,2015

5. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (checkmate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol,2015

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogo;Revista de Gastroenterología de México;2024-02

2. Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer;Cancers;2024-01-24

3. Microbiota-dependent activation of CD4 ⁺ T cells induces CTLA-4 blockade–associated colitis via Fcγ receptors;Science;2024-01-05

4. Corticosteroid-resistant immune-related adverse events: a systematic review;Journal for ImmunoTherapy of Cancer;2024-01

5. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU;Revista Española de Enfermedades Digestivas;2024